【药捷安康-B(02617.HK):替恩戈替尼(TT-00420)被授予治疗MCRPC快速通道认证】智通财经APP讯,药

智通财经
24 Jun
【药捷安康-B(02617.HK):替恩戈替尼(TT-00420)被授予治疗MCRPC快速通道认证】智通财经APP讯,药捷安康-B(02617.HK)发布公告,美国食品药物管理局(“FDA”)授予替恩戈替尼(tinengotinib, TT-00420)治疗转移性去势抵抗性前列腺癌(“mCRPC”)患者的快速通道认证(fast track designation)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10